BaimingXinkang's Novel Antigen-Specific Immunotherapy WP1302 for Graves' Disease Receives FDA Phase II Clinical Clearance

Recently, Worg Pharmaceuticals (Zhejiang) Co., Ltd., a biopharmaceutical company focused on providing breakthrough immunotherapy solutions, announced that the Investigational New Drug (IND) application for Phase II clinical trials of its core product WP1302, a new drug for the treatment of Graves' disease, has been officially approved by the U.S. Food and Drug Administration (FDA). This will bring new treatment options to Graves' disease patients worldwide. Currently, the company is actively preparing to rapidly advance the clinical trials of WP1302 in the United States.

Worg's Innovative Therapy for Graves' Disease (WP1302), Fully Owned with Independent Intellectual Property Rights, Marks a Significant Breakthrough in the Field. Graves' disease, one of the most common autoimmune disorders, affects millions of patients worldwide, with approximately 10 million in Europe and the U.S. alone. The disease primarily manifests as the immune system mistakenly attacking the thyroid gland, causing excessive secretion of thyroid hormones, which leads to symptoms of hyperthyroidism such as weight loss and exophthalmos. As the first and only innovative therapy in the field of Graves' disease treatment in 70 years, WP1302 has already demonstrated significant therapeutic effects in most patients and shown good safety in its Phase 1 clinical trial completed in Europe. The company is highly confident about the upcoming Phase 2 clinical trial in the United States!

Dr. Xu Aiwu, founder, chairman, and CEO of Worg, stated: "We are deeply honored and excited that WP1302 has received FDA approval, which is an initial affirmation of the company's technology platform and product potential, as well as a further demonstration and enhancement of the company’s value. The company will actively advance the development of more product pipelines globally at a faster pace, fully accelerating the integration of clinical and commercialization processes. We hope to benefit more patients as soon as possible and meet unmet treatment needs. With trust and commitment to health, we will join hands with all partners to benefit patients and give back to society and shareholders!"

Dr. Jeffrey Su (Su Yanjing), Co-founder and President of the company, stated: "The approval of WP1302 by the FDA marks a significant milestone in our global pharmaceutical R&D efforts. We are grateful for the professionalism, dedication, and hard work of our team. Currently, the company has made encouraging progress in both internal product pipeline development and external collaborations. WP1302 not only promises higher therapeutic efficacy for patients but will also drive the continuous advancement of our R&D technology platform and commercialization projects on an international scale. We care, We deliver!"

Worg was founded in 2018, focusing on specific immune regulation, using revolutionary innovative technology platforms, integrating global resources, and creating a service platform that combines diagnosis and treatment.

The company owns Apitopes with global full intellectual property rights.^®The technology platform is based on antigen-specific immune tolerance therapy and can be used for the development of a new class of drugs for various autoimmune diseases. The soluble peptide it has pioneered can specifically inhibit the production of autoantibodies, regulate immune balance, target the causes of autoimmune diseases, and is expected to bring new treatment options to patients. This innovative technology is expected to bring new hope for the etiological treatment of autoimmune diseases and bring good news to a large number of patients. At the same time, the company has different product pipelines based on this technology platform, which are also at different clinical stages.

Worg, We Care, We Deliver!